about
Meta-analysis of the comparative efficacy and safety of pitavastatin and atorvastatin in patients with dyslipidaemia.Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia.Statin myopathy: significant problem with minimal awareness by clinicians and no emphasis by clinical investigators.Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children.Is there a role for statins in fungal infections?
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pitavastatin: a new HMG-CoA reductase inhibitor.
@ast
Pitavastatin: a new HMG-CoA reductase inhibitor.
@en
Pitavastatin: a new HMG-CoA reductase inhibitor.
@nl
type
label
Pitavastatin: a new HMG-CoA reductase inhibitor.
@ast
Pitavastatin: a new HMG-CoA reductase inhibitor.
@en
Pitavastatin: a new HMG-CoA reductase inhibitor.
@nl
prefLabel
Pitavastatin: a new HMG-CoA reductase inhibitor.
@ast
Pitavastatin: a new HMG-CoA reductase inhibitor.
@en
Pitavastatin: a new HMG-CoA reductase inhibitor.
@nl
P2093
P2860
P356
P1476
Pitavastatin: a new HMG-CoA reductase inhibitor.
@en
P2093
Brian Wensel
Bruce A Waldrop
Terri M Wensel
P2860
P304
P356
10.1345/APH.1M624
P407
P577
2010-02-23T00:00:00Z